ReviewLife (Basel, Switzerland)2022
The Role of Inflammasomes in Osteoarthritis and Secondary Joint Degeneration Diseases.
Review in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Knowledge mapping of autophagy in osteoarthritis from 2004 to 2022: A bibliometric analysis.Frontiers in immunology · 2023Pooled it
- A Comprehensive Study Utilizing QSAR, Virtual Screening, Molecular Docking, Molecular Dynamics, and MM/GBSA Analyses Reveals Natural Diterpenoids as Promising Caspase-1 Inhibitors.Molecules (Basel, Switzerland) · 2026Article
- Exploring the intricate relationship between IL-1β and IL-18 in the context of osteoarthritis.Frontiers in immunology · 2026Review
- Focus on the NLRP3 inflammasome: its role in the pathogenesis and therapeutic potential of inflammation-driven osteoarthritis.Frontiers in immunology · 2026Review
- Targeting synovial inflammation in knee osteoarthritis: translational insights for diagnosis and therapy.Journal of orthopaedic translation · 2026Review
- Joint Tissues: Convergence and Divergence of the Pathogenetic Mechanisms of Rheumatoid Arthritis and Osteoarthritis.International journal of molecular sciences · 2025Review
- Fibroblast-Myofibroblast Transition in Osteoarthritis Progression: Current Insights.International journal of molecular sciences · 2025Review
- Targeting the NLRP3 inflammasome as a novel therapeutic target for osteoarthritis.Inflammopharmacology · 2025Review
- Anthocyanins and musculoskeletal diseases: mechanisms and therapeutic potential.Frontiers in nutrition · 2025Review
- β-hydroxybutyrate suppresses pathological changes of blood-induced arthropathy in rats.Scientific reports · 2024Article
- Mast Cells Mediate Acute Inflammatory Responses After Glenoid Labral Tears and Can Be Inhibited With Cromolyn in a Rat Model.The American journal of sports medicine · 2024Article
- The Presentation, Clinical Diagnosis, Risk Factors, and Management of Rapidly Progressive Hip Osteoarthritis: A Narrative Literature Review.Journal of clinical medicine · 2024Review
- Cross-species transcriptomics identifies obesity associated genes between human and mouse studies.Journal of translational medicine · 2024Article
- Association between the dietary inflammatory index and all-cause mortality in osteoarthritis.BMC musculoskeletal disorders · 2024Article
- Article
- Roles of the Caspase-11 Non-Canonical Inflammasome in Rheumatic Diseases.International journal of molecular sciences · 2024Review
- Molecular Foundations of Inflammatory Diseases: Insights into Inflammation and Inflammasomes.Current issues in molecular biology · 2024Review
- Fibrotic pathways and fibroblast-like synoviocyte phenotypes in osteoarthritis.Frontiers in immunology · 2024Review
- The protective activity of natural flavonoids against osteoarthritis by targeting NF-κB signaling pathway.Frontiers in endocrinology · 2023Review
- Therapeutic potential of Coptis chinensis for arthritis with underlying mechanisms.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Osteoarthritis is age-related and the most common form of arthritis. The main characteristics of the disease are progressive loss of cartilage and secondary synovial inflammation, which finally result in pain, joint stiffness, and functional disability. Similarly, joint degeneration is characteristic of systemic inflammatory diseases such as rheumatoid arthritis and gout, with the associated secondary type of osteoarthritis. Studies suggest that inflammation importantly contributes to the progression of the disease. Particularly, cytokines TNFα and IL-1β drive catabolic signaling in affected joints. IL-1β is a product of inflammasome activation. Inflammasomes are inflammatory multiprotein complexes that propagate inflammation in various autoimmune and autoinflammatory conditions through cell death and the release of inflammatory cytokines and damage-associated molecule patterns. In this article, we review genetic, marker, and animal studies that establish inflammasomes as important drivers of secondary arthritis and discuss the current evidence for inflammasome involvement in primary osteoarthritis. The NLRP3 inflammasome has a significant role in the development of secondary osteoarthritis, and several studies have provided evidence of its role in the development of primary osteoarthritis, while other inflammasomes cannot be excluded. Inflammasome-targeted therapeutic options might thus provide a promising strategy to tackle these debilitating diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.